Skip to content Skip to footer

#57: 👎 Why Cytonics Turned Down VC

No VC. No Strings. No Compromise.

Venture Capital is the kiss of death for biotech.

They swoop in with fat checks, then slowly strangle the company—loading it with liquidation preferences, board control, and demands that serve their fund, not the mission. The result? Innovation gets boxed in. Shareholders get diluted. And the science bends to Wall Street’s quarterly whims.

That’s not us.

Cytonics has never taken a single dime of venture capital—and we never will. We’ve raised over $25 million entirely from individuals like you. People who actually care about building something real, not about hitting an artificial exit timeline.

Equity crowdfunding flips the script:

  • Alignment of interests – no VC middlemen skimming value before anyone else.
  • Democratization – everyday investors get access to deals historically reserved for insiders.
  • Grassroots power – over 7,000 shareholders strong, united in funding the future of joint health.

This isn’t “pay-to-play biotech.” This is biotech funded by the people, for the people.

And it’s working. Every milestone we’ve hit—our patents, our clinical trial progress, our transition to a true clinical-stage biotech—was fueled by the collective power of our community. Not a single venture firm.

Venture capital destroys companies. Crowdfunding builds them.

That’s why Cytonics is still ours.

And yours.

Appreciatively,

Joey Bose

President & CEO

Leave a comment

0.0/5

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA’s BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Receive News

Download Exclusive Investor Presentation & Stay Updated